Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | CTSE | P14091 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13243425 | 0.91 | HPGD (0.44) | HPGDRECQLCHRM1EPHX1KDM4E | |
| SCHEMBL117231 | 0.91 | HPGD (0.48) | HPGDRECQLCHRM1EPHX1KDM4E | |
| SCHEMBL8018 | 0.90 | HPGD (0.58) | HPGDRECQLEPHX1KDM4EMAPT | |
| SCHEMBL14480194 | 0.89 | RECQL (0.52) | HPGDRECQLCHRM1EPHX1KDM4E | |
| Hydrochloric Acid SCHEMBL307023 | 0.89 | HPGD (0.57) | HPGDRECQLEPHX1KDM4EMAPT | |
| SCHEMBL4163940 | 0.88 | HPGD (0.47) | HPGDRECQLCHRM1EPHX1KDM4E | |
| SCHEMBL372744 | 0.88 | HPGD (0.47) | HPGDRECQLCHRM1EPHX1KDM4E | |
| SCHEMBL1675672 | 0.88 | HPGD (0.50) | HPGDRECQLEPHX1KDM4EMAPT | |
| SCHEMBL310354 | 0.86 | HPGD (0.51) | HPGDRECQLCHRM1EPHX1KDM4E | |
| SCHEMBL1085082 | 0.86 | HPGD (0.51) | HPGDRECQLCHRM1EPHX1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4685141-A1 | ISOINDOLINE DERIVATIVE, BENZOINDOLE DERIVATIVE AND USE THEREOF | Shanghai Helioson Pharmaceutical Co., Ltd. (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-20250195513-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2025-06-19 | — | — | US | disclosed |
| WO-2025106910-A1 | DEGRADER MOLECULES TARGETING ANDROGEN RECEPTOR | FLARE THERAPEUTICS INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4536664-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BeiGene, Ltd. (KY) | 2025-04-16 | — | — | EP | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| CN-119403805-A | Degradation of IRAK4 by conjugation of IRAK4 inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20240246920-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | KING'S COLLEGE LONDON (GB) | 2024-07-25 | — | — | US | disclosed |
| CN-118359600-A | Aryl imidazolyl isoxazole compound as well as preparation method and application thereof | 中国科学院广州生物医药与健康研究院 | 2024-07-19 | — | — | CN | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3844159-A1 | NOVEL PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-07-07 | — | — | EP | disclosed |
| CN-112638901-A | Novel pyrrolidinylamide compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2021-04-09 | — | — | CN | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020043271-A1 | NOVEL PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-05 | — | — | WO | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| US-20060148800-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HPGD 3843/4885RECQL 2866/4885CHRM1 4719/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HPGD 3843/4885RECQL 2866/4885CHRM1 4719/4885 |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | HPGD 3639/4885RECQL 50/4885CHRM1 1756/4885 |
| US-20240246920-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | RIF1, NAT1, POLR1C | HPGD 3094/4885RECQL 203/4885CHRM1 954/4885 |
| US-20250195513-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | IRAK4, IRAK2, IRAK3 | HPGD 4611/4885RECQL 2361/4885CHRM1 4749/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HPGD 3843/4885RECQL 2866/4885CHRM1 4719/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | HPGD 3639/4885RECQL 50/4885CHRM1 1756/4885 |
| US-20060148800-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | HPGD 3639/4885RECQL 50/4885CHRM1 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.